Management of acquired haemophilia is not covered in this guideline. Contact haematologist on-call for advice

RECOGNITION AND ASSESSMENT

Known patients with inherited bleeding disorder

Inherited bleeding disorders

  • Factor VIII deficiency (Haemophilia A)
  • Factor IX deficiency (Haemophilia B)
  • Factor XI deficiency (Haemophilia C)
  • von Willebrand factor deficiency (vW disease)
  • Hereditary intrinsic platelet defects (rare)
  • Deficiency of other coagulation factors (rare) 

Haemophilia A and B

Severity

  • Baseline plasma concentration of Factor VIII/IX as % of normal:
    • mild (6–40%): muscle and joint bleeds, usually following trauma
    • moderate (1–5%): muscle and joint bleeds, usually following trauma
    • severe (<1%): spontaneous joint and muscle bleeds

Presentation

  • X-linked inheritance occurring almost exclusively in men
    • rarely female haemophilia carrier may have mild bleeding
  • Most patients present with muscle or joint bleeds
  • Minor bleeds usually present with
    • pain and slight restriction of movement
    • minimal or no joint swelling
  • Major bleeds present with:
    • severe pain/tenderness
    • marked swelling and restriction of movements of the joint
  • Head injury or suspected intracranial bleed
    • administer appropriate factor concentrate immediately
    • arrange urgent CT scan of head
    • Do not wait for scan before starting treatment
  • Other bleeding manifestations (e.g. GI bleeding, haematuria) usually associated with an underlying pathology
  • Be alert for a major bleed into psoas muscle
    • symptoms include pain in groin, abdomen or lower spine, hip in flexion, inability to sit, stand, weight bear or lie straight, numbness, paraesthesia over thigh region

Von Willebrand’s disease

  • Affects men and women
  • Usually presents with:
    • mucocutaneous bleeding
    • frequent and prolonged epistaxis
    • menorrhagia
    • easy bruising

IMMEDIATE TREATMENT

  • Treat all bleeds without delay
    • call blood bank for factor preparations
    • ask to process urgently
  • Treatment of significant bleeds usually involves administration of clotting factors/desmopressin:
    • in Haemophilia A: recombinant Factor VIII (Advate® or Elocta®) given as slow IV bolus or desmopressin given SC or IV infusion over 20 min
    • in Haemophilia B: recombinant Factor IX (Benefix® or Alprolix®) given as slow IV bolus
    • in von Willebrand’s disease: Desmopressin or vW factor concentrate (Voncento® or Veyvondi®) given as slow IV bolus
  • Avoid aspirin or non-steroidal anti-inflammatory drugs for analgesia

Haemophilia A

Minor muscle or joint bleed

Major muscle/joint bleed

  • Admit patient and inform on-call haematology consultant/SpR
  • In Haemophilia A of any severity, give Factor VIII concentrate to raise factor level to 80–100%
  • Rest joint for at least 1 day, prescribe appropriate analgesia
  • Do not administer IM injections
  • Check for neurological deficit
    • femoral nerve in a psoas bleed
    • median nerve compression in carpal tunnel with a forearm bleed

Head injury or suspected intracranial bleed

  • Admit patient and inform on-call haematology consultant/SpR
  • In Haemophilia A of any severity, give Factor VIII concentrate immediately to raise factor level to 80–100%
    • administer appropriate Factor VIII concentrate immediately
    • arrange urgent CT scan of head
  • Do not wait for scan before starting treatment

Further therapy

  • Monitor factor level with advice from haematology team
  • Repeated doses of Factor VIII concentrate may be required at 12-24 hrly intervals

Haemophilia B

  • Desmopressin has no role in treating Haemophilia B

Minor muscle or joint bleeds

  • Give Factor IX concentrate to raise level to 30–50% 

Major muscle/joint bleeds or head injuries

  • Admit patient and inform on-call haematology consultant/SpR
  • In Haemophilia B of any severity, give Factor IX concentrate(Benefix® or Alprolix®) to raise level to 50–80%
    • factor IX level higher than 80% is a risk for venous thrombosis
  • Rest joint for at least 1 day and prescribe appropriate analgesia
  • Check for neurological deficit
    • femoral nerve in a psoas bleed
    • median nerve compression in carpal tunnel with a forearm bleed

Head injury or suspected intracranial bleed

  • Admit patient and inform on-call haematology consultant/SpR
  • In Haemophilia B of any severity, give Factor IX concentrate immediately to raise level to 50–80%,
    • factor IX level higher than 80% is a risk for venous thrombosis
    • arrange urgent CT scan of head
  • Do not wait for scan before starting treatment

Further therapy

  • Monitor factor level with advice from haematology team
  • Repeated doses of Factor IX concentrate may be required once daily

Patients with von Willebrand’s disease or hereditary platelet disorders

  • Discuss with on-call haematology consultant/SpR
  • Use local measures to stop bleeding (e.g. nasal packing, etc)
  • Give tranexamic acid 1 g oral 8-hrly
Other treatment

Patients with other coagulation factor deficiencies or other bleeding manifestations

  • Contact on-call haematology consultant/SpR

USE OF COAGULATION FACTOR CONCENTRATES

  • Coagulation factor concentrates are available from hospital blood bank
  • Before initiating treatment, discuss management with on-call haematology consultant/SpR to decide:
    • factor concentrate required, dose, frequency and duration of treatment
    • monitoring of pre- and post-infusion percentages (if required)
  • Document use of any factor concentrate (including dose and time given) on treatment chart
  • If patient admitted, monitor carefully to ensure bleeding has stopped

Calculation of factor dose

  • Give individual patients same brand of concentrate each time treatment is required
    • information in medical record or in blood bank

Step 1: calculate factor increment required (%)

  • Factor increment required = desired factor level – baseline factor level of patient

Step 2: calculate dose of specific factor required

  • For Factor VIII concentrates (Advate or Elocta)
    • dose required (in units) = body weight (kg) x factor increment required x 0.5
  • For Factor IX concentrate (Benefix, Alprolix)
    • dose required (in units) = body weight (kg) x factor increment increase required x 1.2
  • For vW Factor concentrate (Voncento, Veyvondi)
  • Dose required (in RIC units) = 40–80 units (RIC activity) × body weight (kg)
    • RIC = Ristocetin co-factor activity

Administration

Reconstitution of factor concentrate

Always wear gloves
  • Check dosage of factor to be given
    • order appropriate factor concentrate from main blood bank
  • Most factor concentrates are provided in packs with:
    • concentrate powder
    • diluent in syringe
    • vial adapter for transfer of diluent
    • infusion set
  • Read instructions carefully before reconstituting factor
    • a clear step by step guide is in each package
    • incorrect reconstitution may result in wastage of expensive concentrate
  • If in doubt, seek advice from haematology nurses or haemophilia nurse specialist

Drawing up

  • Transfer diluent into dried concentrate vial via a needleless adapter
  • Ensure no concentrate remains undissolved
  • Draw up concentrate into a syringe

Administering

  • Administer concentrate via IV cannula as a slow bolus, flush cannula with normal saline
    • remove cannula at the time of discharge
  • Record dose administered and date and time in patient notes and treatment chart
  • Return any unused concentrate (even if pack opened) to hospital blood bank

Post administration

  • Observe patient after administration for 30 min
  • Discard all used bottles and needles into sharps bin
  • Record dose administered and date and time in patient notes and treatment chart
  • Return any unused concentrate (even if pack opened) to hospital blood bank

Allergic reactions

  • Uncommon
    • more common to react to factor IX
    • If reaction occurs, treat with chlorphenamine +/- hydrocortisone

DISCHARGE

  • Inform haemophilia nurse specialist
    • all bleeding disorder patients admitted with a bleed will be reviewed by haematology team the following working day
  • Remove cannula

© 2022 The Bedside Clinical Guidelines Partnership.

Created by University Hospital North Midlands and Keele University School of Computing and Mathematics.

Research and development team: James Mitchell, Ed de Quincey, Charles Pantin, Naveed Mustfa